therascreen PIK3CA RGQ PCR Kit
QIAGEN GmbH · Decision date Oct 22, 2025
What did the FDA approve?
FDA records P190001/S002 as a supplement to PMA P190001, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 22, 2025.
FDA approval order statement
Approval for a software update for the therascreen PIK3CA RGQ PCR Kit
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Medical Genetics
- Decision date
- Oct 22, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P190001/S002
- Regulatory pathway
- PMA supplement
- Applicant
- QIAGEN GmbH
- Product code
- OWD
- Decision code
- APPR
- Decision date
- Oct 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- QIAGEN GmbH
- Product code
- OWD
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190001/S002 received
Application receipt date recorded by FDA.
P190001/S002 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P190001. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
QIAGEN GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Qiagen Strasse 1, Hilden, 40724
Sources and methodology
- Original FDA record: P190001/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



